openPR Logo
Press release

Primary Ciliary Dyskinesia Market and Epidemiology 2034: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | ReCode Therapeutics, University of North Carolina, Parion Sciences, Ethris GmbH

05-29-2024 07:46 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Primary Ciliary Dyskinesia Market and Epidemiology 2034:

DelveInsight's "Primary Ciliary Dyskinesia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Primary Ciliary Dyskinesia, historical and forecasted epidemiology as well as the Primary Ciliary Dyskinesia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Primary Ciliary Dyskinesia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Ciliary Dyskinesia Market Forecast
https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Primary Ciliary Dyskinesia Market Report:
• The Primary Ciliary Dyskinesia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• According to research led by Hannah et al. (2022), the overall prevalence of Primary Ciliary Dyskinesia (PCD) is typically cited to range from 1 in 11,000 to 1 in 16,000. However, these prevalence figures were established before the identification of genes responsible for PCD and are subject to significant limitations.
• According to the NHS Foundation Trust, Primary Ciliary Dyskinesia (PCD) is considered a relatively uncommon condition in the UK, with approximately 3,000 reported cases. The prevalence of PCD in the UK is estimated to be around 1 in 7,500 individuals.
• Key Primary Ciliary Dyskinesia Companies: RReCode Therapeutics, University of North Carolina, Parion Sciences, Ethris GmbH, and others
• Key Primary Ciliary Dyskinesia Therapies: RCT1100, Albuterol, P-1037 IS/VX-371, ETH-42, and others
• The Primary Ciliary Dyskinesia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Primary Ciliary Dyskinesia pipeline products will significantly revolutionize the Primary Ciliary Dyskinesia market dynamics.

Primary Ciliary Dyskinesia Overview
Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder that affects the function of cilia, which are tiny, hair-like structures found on the surface of cells lining the respiratory tract, sinuses, ears, and reproductive organs. Cilia play a crucial role in clearing mucus and debris from the airways, aiding in breathing and protecting against infections.

Get a Free sample for the Primary Ciliary Dyskinesia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Ciliary Dyskinesia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Primary Ciliary Dyskinesia Epidemiology Segmentation:
The Primary Ciliary Dyskinesia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Primary Ciliary Dyskinesia
• Prevalent Cases of Primary Ciliary Dyskinesia by severity
• Gender-specific Prevalence of Primary Ciliary Dyskinesia
• Diagnosed Cases of Episodic and Chronic Primary Ciliary Dyskinesia

Download the report to understand which factors are driving Primary Ciliary Dyskinesia epidemiology trends @ Primary Ciliary Dyskinesia Epidemiology Forecast
https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Ciliary Dyskinesia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Ciliary Dyskinesia market or expected to get launched during the study period. The analysis covers Primary Ciliary Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Primary Ciliary Dyskinesia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Primary Ciliary Dyskinesia Therapies and Key Companies
• RCT1100: ReCode Therapeutics
• Albuterol: University of North Carolina
• P-1037 IS/VX-371: Parion Sciences
• ETH-42: Ethris GmbH

Discover more about therapies set to grab major Primary Ciliary Dyskinesia market share @ Primary Ciliary Dyskinesia Treatment Landscape
https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Primary Ciliary Dyskinesia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Primary Ciliary Dyskinesia Companies: ReCode Therapeutics, University of North Carolina, Parion Sciences, Ethris GmbH, and others
• Key Primary Ciliary Dyskinesia Therapies: RCT1100, Albuterol, P-1037 IS/VX-371, ETH-42, and others
• Primary Ciliary Dyskinesia Therapeutic Assessment: Primary Ciliary Dyskinesia current marketed and Primary Ciliary Dyskinesia emerging therapies
• Primary Ciliary Dyskinesia Market Dynamics: Primary Ciliary Dyskinesia market drivers and Primary Ciliary Dyskinesia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Primary Ciliary Dyskinesia Unmet Needs, KOL's views, Analyst's views, Primary Ciliary Dyskinesia Market Access and Reimbursement

To know more about Primary Ciliary Dyskinesia companies working in the treatment market, visit @ Primary Ciliary Dyskinesia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Primary Ciliary Dyskinesia Market Report Introduction
2. Executive Summary for Primary Ciliary Dyskinesia
3. SWOT analysis of Primary Ciliary Dyskinesia
4. Primary Ciliary Dyskinesia Patient Share (%) Overview at a Glance
5. Primary Ciliary Dyskinesia Market Overview at a Glance
6. Primary Ciliary Dyskinesia Disease Background and Overview
7. Primary Ciliary Dyskinesia Epidemiology and Patient Population
8. Country-Specific Patient Population of Primary Ciliary Dyskinesia
9. Primary Ciliary Dyskinesia Current Treatment and Medical Practices
10. Primary Ciliary Dyskinesia Unmet Needs
11. Primary Ciliary Dyskinesia Emerging Therapies
12. Primary Ciliary Dyskinesia Market Outlook
13. Country-Wise Primary Ciliary Dyskinesia Market Analysis (2020-2034)
14. Primary Ciliary Dyskinesia Market Access and Reimbursement of Therapies
15. Primary Ciliary Dyskinesia Market Drivers
16. Primary Ciliary Dyskinesia Market Barriers
17. Primary Ciliary Dyskinesia Appendix
18. Primary Ciliary Dyskinesia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

Graft Versus Host Disease Market http://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft-versus-host Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Graft-versus-host Disease, historical and forecasted epidemiology as well as the Graft-versus-host Disease market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Implantable Cardioverter Defibrillators Market http://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
DelveInsight's 'Implantable Cardioverter Defibrillators (ICDs) - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Implantable Cardioverter Defibrillators (ICDs) and the historical and forecasted Implantable Cardioverter Defibrillators (ICDs) market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Ciliary Dyskinesia Market and Epidemiology 2034: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | ReCode Therapeutics, University of North Carolina, Parion Sciences, Ethris GmbH here

News-ID: 3518630 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Cilia

What is behind the Rise of the Fluorochemicals Market? | Top Key Players are Rec …
As per a research report by Global Market Insights, Inc., global erdosteine market is estimated to surpass $160 million through 2025. Erdosteine is utilized in the production of medicines that regulate mucus production. Erdosteine has antibacterial and mucolytic properties which helps in mucus production’s regulation. Escalating demands for mucus regulating medicines due to the rising level of air pollution is expected to boost global erdosteine market trends in the forecast
COVID-19 to Impact Demand Growth of Erdosteine Market | Top Key Players are Reci …
Global Market Insights, Inc. says that the erdosteine market could surpass USD 160 million by 2025. Driven by growing occurrences of common respiratory issues like cold, bronchitis, and cough, the global erdosteine market is estimated to observe significant profits through 2025. Erdosteine has a broad range of applications in the production of drugs to ameliorate and control the symptoms that arise due to excessive mucus production, which is likely to
Erdosteine Market to see 8% CAGR till 2025 | Top Key Players are Recipharm AB, T …
Escalating demands for mucus regulating medicines due to the rising level of air pollution is expected to boost global erdosteine market trends in the forecast years. Erdosteine is an active pharmaceutical ingredient that is used to manufacture drugs that alleviate cold symptoms by making mucus less viscous and sticky and opening up airways. Get sample copy of this research report @ https://www.gminsights.com/request-sample/detail/3371 Driven by growing occurrences of common respiratory issues like cold,
Ciliary Dyskinesia Market by Symptoms, Causes, Tests, and Diet 2023
Market Highlights Primary ciliary dyskinesia (PCD) is a type of respiratory tract infections that affects the motility functions of cilia in various organs and cells of the human body. The organ system that is primarily affected in this disease is the respiratory system, where cilia beat continuously to remove mucus that traps inhaled pollutants and pathogens. GET SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/4419 The major symptoms are sinuses, chronic nasal congestion, runny nose with
Primary Ciliary Dyskinesia Market is Trending with CAGR of 6.7% by 2023, Key Pla …
New Report on "Global Primary Ciliary Dyskinesia Market" added to marketresearchfuture.com database. The research report offers a detailed analysis of the market providing insights into the market dynamics that are expected to influence the overall market positively in the next few years. Global Primary Ciliary Dyskinesia Market -Highlights Primary ciliary dyskinesia (PCD) is a type of respiratory tract infections that affects the motility functions of cilia in various organs and cells
Primary Ciliary Dyskinesia Market is Trending with CAGR of 6.7% by 2023, Key Pla …
Market Research Future recently announced the addition of a new research study to its comprehensive collection of research reports. The report Global Primary Ciliary Dyskinesia Market 2018 offers vital insights on every market segment in terms of market size analysis for automotive hybrid fuel sensors across the different regions. Global Primary Ciliary Dyskinesia Market -Highlights Primary ciliary dyskinesia (PCD) is a type of respiratory tract infections that affects the motility functions of